A Double-blind, Placebo-controlled, Three-way Crossover Study to Compare the Safety and Efficacy of 8 Days of Therapy With ONO-6950 Versus Placebo and Montelukast (Singulair) on Asthmatic Responses and Airway Hypersensitivity Following Allergen Challenge in Patients With Asthma.

Trial Profile

A Double-blind, Placebo-controlled, Three-way Crossover Study to Compare the Safety and Efficacy of 8 Days of Therapy With ONO-6950 Versus Placebo and Montelukast (Singulair) on Asthmatic Responses and Airway Hypersensitivity Following Allergen Challenge in Patients With Asthma.

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Sep 2014

At a glance

  • Drugs Gemilukast (Primary) ; Montelukast
  • Indications Asthma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 01 Apr 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 01 Mar 2013 Planned End Date changed from 1 Feb 2013 to 1 Apr 2013 as reported by ClinicalTrials.gov.
    • 01 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top